Oncor
This article was originally published in The Gray Sheet
Executive Summary
Plans to file an appeal "in the near future" against de-listing proceedings initiated by the American Stock Exchange, the firm reports. Due to the firm's "history of losses and other related factors, the company continues to be below certain guidelines for continuing listing of its common stock on the exchange," Oncor explains. The Gaithersburg, Maryland maker of gene-based cancer test systems is seeking to "recapitalize its capital structure through the infusion of additional capital" to enhance its financial position